The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
about
Terazosin for benign prostatic hyperplasiaCurrent medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitationsα1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?Terazosin for benign prostatic hyperplasia.Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects.Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy.Emerging drug therapies for benign prostatic hyperplasia.Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life.Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Definition of at-risk patients: baseline variables.A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasiaMeasurement of benign prostatic hyperplasia treatment effects on male sexual function.Review of exercise and the risk of benign prostatic hyperplasia.The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.Placebo Medication and Sham Surgery Responses in Benign Prostatic Hyperplasia Treatments: Implications for Clinical Trials.Adherence and Persistence Patterns in Medication Use Among Men With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.Use of meta-analytic results to facilitate shared decision makingTwelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.Quantitative evaluation of prostatectomy for benign prostatic hypertrophy under a national health insurance law: a multi-centre study.Drug or symptom-induced depression in men treated with alpha 1-blockers for benign prostatic hyperplasia? A nested case-control study.
P2860
Q24234560-F8C181E1-FB61-464B-A3A5-C9C11DFEFF75Q24649617-F4AD398C-D47F-4909-A0B4-C7CD958C64AFQ28070342-FB48767A-C8D0-41DC-A59F-721D3466EB8CQ30880131-6EC8D767-270C-4F8D-9EBE-BACE1B3588B3Q33146637-5B2BF7B0-C63C-4634-BB77-D62445E6007CQ34003918-7E22AA20-0B76-43E1-81D1-C1585920677DQ34171403-7E47D5CE-492C-40BC-9F36-CC8B0881AA30Q34565171-A34F5961-1F15-4088-B230-AE8CB6D517FAQ35204840-8E6725F6-86B4-4560-87CA-E35C81C8A14CQ35803156-172C1C41-0FFD-4017-84E6-F95A3D353970Q35919193-82678A2C-D4FC-44E2-8A01-F8EFE7D15E02Q36371582-08E052F8-25CD-4B39-9476-E367AD999375Q36409125-B8362532-F57D-411F-9811-3213009C3CF8Q37281116-B7910810-C5AF-4DAD-A0F1-67D18BC4BBF0Q37523227-46B96B20-A04B-4C19-BC08-F5FA93718AD4Q37667615-BB47DCA1-5543-4D61-A0B5-B8C70302EEC7Q38364582-F47A0B8C-3416-4E73-892A-3B37AB098FB0Q38573073-1B0243AF-F3D2-45BC-953F-6ABC77F86A34Q39179811-96B0DD83-2F3D-49B9-A13C-0B22E20774E6Q39274525-8D6196F3-9D3F-403C-AD29-917A28C37CD3Q39284036-CB9188F5-D58E-4657-A081-DCA9D127A770Q41469996-84F817EC-F842-4C9A-9A3C-18961463E089Q41592575-323C26F5-F9C9-4566-9FCF-40A5EAC11DE6Q41610309-BEB9E267-1506-41D9-B022-0BB53D909382Q42539019-44F48889-AB0A-4AC3-A16E-7EDB0D4EE835Q42671633-F6EC893C-FA6B-487F-A816-5A3D65BB50A0Q43947333-385BD68E-DAB2-4C7B-9FAD-CF4BC2F19F9C
P2860
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@en
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@nl
type
label
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@en
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@nl
prefLabel
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@en
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@nl
P2093
P1433
P1476
The Hytrin Community Assessmen ...... sia. HYCAT Investigator Group.
@en
P2093
Auerbach S
Oesterling JE
Roehrborn CG
P304
P356
10.1016/S0090-4295(99)80409-9
P407
P577
1996-02-01T00:00:00Z